Scientists at McMaster University have discovered several new biomarkers from a single drop of blood that could allow earlier and more definitive detection of cystic fibrosis (CF), a genetic disease which strikes both children and adults, causing chronic problems with the digestive system and the lungs.
The findings, published online in the Journal of Proteome Research, are significant because current newborn screening methods are not accurate enough to identify the disorder in the population, which can manifest itself in many different ways, requiring additional testing and causing further stress for anxious parents.
“The earlier CF is detected, the earlier it can be managed and treated, which means better health outcomes for affected infants, including their future growth and development,” says Philip Britz-McKibbin, lead author of the study and a professor in McMaster’s Department of Chemistry & Chemical Biology, who conducted the research with graduate student Alicia DiBattista, now a postdoctoral fellow at Newborn Screening Ontario (NSO).
A tiny amount of blood is drawn from the heel of all babies as part of universal newborn screening programs that test for many rare yet treatable diseases since babies usually have no signs of disease at birth, including CF.
In the case of CF, infants are screened for a pancreatic enzyme and then a panel of disease-causing genetic mutations associated with CF. However, further testing to confirm or rule out the disease finds that most babies who screen-positive do not actually have the disease. These babies are later found to be “healthy carriers” or their results are deemed to be “false positives”.
With this in mind, researchers set out to determine whether they could discover chemical signatures in a dried blood spot that could better distinguish infants who have CF from those who do not.
Using less than a single drop of blood stored at NSO at CHEO, a pediatric health and research centre in Ottawa, researchers analyzed and compared samples from infants confirmed to have CF with the samples of both healthy and screen positive infants. They found several new compounds as well as simple amino acids directly related to affected infants with CF who otherwise have no symptoms and normal birth weight.
“These biomarkers provide new insights into the disease process early in life before symptoms are fully apparent,” says Britz-McKibbin. “Moreover, these compounds can be analyzed by mass spectrometry at incremental costs since it is already used for testing many other genetic diseases at newborn screening facilities around the world”
“Ontario started screening for Cystic Fibrosis in April 2007, and since that time over 400 children have already benefited from early recognition and early treatment. But for every one of these children, about 10 have had a false-positive result. We want to get this number down and are very hopeful that the new biomarkers discovered by this research project will help us do exactly that,” says Pranesh Chakraborty, medical director of NSO at CHEO.
In Canada, life expectancy rates have risen dramatically with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition, lung transplants. The advent of universal newborn screening programs for CF will likely further improve the quality of life of affected patients.
“We know that early detection can have significant benefits for people living with cystic fibrosis,” said Dr. John Wallenburg, chief scientific officer at Cystic Fibrosis Canada. “The current screening methodologies capture a broad swathe of families that then need further testing to narrow down those that are true positives. The anxiety and distress that such further testing can needlessly cause families was a major concern that slowed the adoption of newborn screening in some jurisdictions. Dr. Britz-McKibbin’s data provide insights for more specific newborn screening, as well as early manifestations of the disease.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosison November 18, 2019 at 4:14 pm
Secondary efficacy outcomes include other measures of pulmonary exacerbations, change in forced expiratory volume in 1 second (FEV1), % predicted, and change in Cystic Fibrosis Questionnaire-Revised ...
- Jersey follows UK with cystic fibrosis drugs dealon November 18, 2019 at 4:09 pm
Three cystic fibrosis drugs will be available to Jersey residents under an agreement between the island's government and the manufacturer Vertex. A government spokesman said the deal was similar to ...
- Guernsey secures cystic fibrosis drugs Orkambi and Symkevi dealon November 18, 2019 at 4:07 pm
A deal to supply two drugs described as "life-extending" for people living with cystic fibrosis has been agreed for the Bailiwick of Guernsey. Health authorities began to speak with manufacturers ...
- Life's Greatest Gifts: Breakthrough drug could mean second life for cystic fibrosis patientson November 13, 2019 at 7:33 pm
Others will spend the holiday in the hospital, or stay as hopeful as possible they'll even make it another day. Dan Beach doesn't like to live that way. His cystic fibrosis affects nearly every part ...
- Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UKon November 13, 2019 at 4:55 am
Vertex Pharmaceuticals Inc's drugs for lung condition cystic fibrosis will now be available to patients across the UK after the company reached a pricing deal with Wales on Wednesday.
- Vertex reaches deal with Wales for cystic fibrosis treatmenton November 13, 2019 at 4:18 am
(Reuters) - Vertex Pharmaceuticals Inc said on Wednesday cystic fibrosis patients in Wales would get access to the company’s life-extending drugs following an agreement with the state-funded health ...
- California Boy with Cystic Fibrosis Gets His Wish of Traveling to Paris Grantedon November 12, 2019 at 2:40 pm
A 10-year-old boy with an incurable disease got the surprise of his life when his wish for traveling abroad was granted.
- Study reveals 'bug wars' that take place in cystic fibrosison November 12, 2019 at 11:06 am
Scientists have revealed how common respiratory bugs that cause serious infections in people with cystic fibrosis interact together, according to a new study in eLife. The results provide insights ...
- Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicineson November 12, 2019 at 6:51 am
This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance ...
- Cystic fibrosis patients living longer and new therapy offers even more hopeon November 12, 2019 at 4:17 am
Frank Carter has already lived well beyond his life expectancy. The 68-year-old Circleville resident has cystic fibrosis, a life-threatening genetic disease that shortens the average life expectancy ...
via Bing News